Deficiency of a novel lncRNA-HRAT protects against myocardial ischemia reperfusion injury by targeting miR-370-3p/RNF41 pathway

Xinbin Zheng¹,², Ting Zhong¹, Fan Yu³,⁴, Jingsi Duan³,⁴, Yao Tang¹, Yaxiu Liu¹, Mingrui Li¹, Deqiang Sun³,⁴ and Deling Yin³,⁴*

¹Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China, ²Clinical Research Center, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, China, ³Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ⁴Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, China

Accumulating evidence indicates that long non-coding RNAs (lncRNAs) contribute to myocardial ischemia/reperfusion (I/R) injury. However, the underlying mechanisms by which lncRNAs modulate myocardial I/R injury have not been thoroughly examined and require further investigation. A novel lncRNA named lncRNA-hypoxia/reoxygenation (H/R)-associated transcript (lncRNA-HRAT) was identified by RNA sequencing analysis. The expression of lncRNA-HRAT exhibited a significant increase in the I/R mice hearts and cardiomyocytes treated with H/R. LncRNA-HRAT overexpression facilitates H/R-induced cardiomyocyte apoptosis. Furthermore, cardiomyocyte-specific deficiency of lncRNA-HRAT in vivo after I/R decreased creatine kinase (CK) release in the serum, reduced myocardial infarct area, and improved cardiac dysfunction. Molecular mechanistic investigations revealed that lncRNA-HRAT serves as a competing endogenous RNA (ceRNA) of miR-370-3p, thus upregulating the expression of ring finger protein 41 (RNF41), thereby aggravating apoptosis in cardiomyocytes induced by H/R. This study revealed that the lncRNA-HRAT/miR-370-3p/RNF41 pathway regulates cardiomyocyte apoptosis and myocardial injury. These findings suggest that targeted inhibition of lncRNA-HRAT may offer a novel therapeutic method to prevent myocardial I/R injury.

KEYWORDS
lncRNA-HRAT, ischemia/reperfusion, miR-370-3p, RNF41, apoptosis, myocardial injury

Abbreviations: I/R, ischemia/reperfusion; lncRNA, long non-coding RNA; H/R, hypoxia/reoxygenation; HRAT, hypoxia/reoxygenation-associated transcript; CASP3, caspase-3; miRNA – microRNA; FISH, fluorescence in situ hybridization; RNF41, ring finger protein 41; TTC, 2,3,5-triphenyl tetrazolium chloride; CK, Creatine kinase; RIP, RNA immunoprecipitation.
Introduction

Ischemic heart disease is the most common type of cardiovascular disease and a primary cause of death worldwide (1, 2). Clinical treatment for myocardial infarction is effective and includes thrombolytic therapy, revascularization by percutaneous coronary intervention, or coronary artery bypass graft surgery (3). However, myocardial reperfusion induces additional death of cardiomyocytes and an increase in infarct size, a condition known as myocardial ischemia and reperfusion (I/R) injury (4–6). Over the past decades, many bioprocesses and molecular mechanisms have been shown to participate in myocardial I/R injuries, such as apoptosis, autophagy, ferroptosis, oxygen species generation, calcium overloading, and the inflammatory response (7–9). However, the mechanisms underlying myocardial I/R injury remain unclear.

As a subgroup of non-coding RNAs (ncRNAs), the general definition of long non-coding RNAs (lncRNAs) is the presence of more than 200 nt transcripts with a lack of functional coding capacity (10). Recent studies have revealed that interactions exist between lncRNAs and genetic material (DNA and RNA) as well as between their gene products (proteins), and lncRNAs regulate many genes through various mechanisms, thereby impacting diverse cellular pathways (11). LncRNAs are implicated in various pathological and physiological processes, such as cardiovascular disease and cancer (12–14). LncRNAs have been shown to regulate the initiation and progression of cardiovascular disease (15). Some lncRNAs are abnormally expressed in the heart during the early period of reperfusion after ischemia (16). Several studies have suggested that lncRNAs play a vital role in myocardial I/R injury. For example, lncRNA-H19 alleviates cardiomyocyte apoptosis and myocardial I/R injury by inhibiting the mitochondrial apoptotic pathway mediated by Bcl-2 (17). Inhibition of lncRNA-TUG1 ameliorates myocardial injury by upregulating high mobility group protein 1 (HMGB1) and Rac1 (18). In addition, upregulated lncRNA-RMRP aggravates myocardial I/R injury by downregulating miR-206 and upregulating ATG3 subsequently (19). However, the intervention by these lncRNAs only partially improved myocardial I/R injury. The existence of other lncRNAs that regulate myocardial I/R injury requires further investigation.

MicroRNAs (miRNAs) are endogenous, non-coding small RNA molecules composed of approximately 20 nucleotides. miR-370-3p is located in the DLK1/DIO3 domain and has been identified as a cancer-related genomic region in Human chromosome 14 (20). Previous studies have shown that miR-370-3p acts as a tumor suppressor and inhibits the proliferation and invasion of various tumor cells (21–23). Recently, as direct targets of cirRNA-0010729, cirRNA-0023461, and cirRNA-TRRAP, miR-370-3p has been shown to protect cardiomyocytes from hypoxia-induced cardiomyocyte injury (24–26). However, the role of miR-370-3p in myocardial I/R injury remains unclear.

In this study, in vitro and in vivo experiments were performed to explore the role of a novel lncRNA in myocardial I/R injury and the underlying mechanism of this process. RNA sequencing analysis revealed that a novel lncRNA named lncRNA-hypoxia/reoxygenation (H/R)-associated transcript (lncRNA-HRAT) was significantly induced in H/R-cardiomyocytes and I/R-myocardium. Furthermore, we found that upregulated lncRNA-HRAT reduced the expression of the neighboring gene adenosine A1 receptor (Adora1). In addition, lncRNA-HRAT serves as a competing endogenous RNA (ceRNA) of miR-370-3p, promoting the expression of ring finger protein 41 (RNF41), thereby aggravating apoptosis triggered by H/R in cardiomyocytes. Finally, in vivo studies revealed the mechanisms by which lncRNA-HRAT regulated myocardial I/R injury. In summary, these findings offer novel insights into myocardial I/R injury therapies.

Materials and methods

Cell culture and treatment

Cardiac muscle cell line H9c2, obtained from the Cell Bank of the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, was supplemented with 100 µg/mL streptomycin, 100 U/mL penicillin G, and 10% fetal bovine serum, DMEM, and cultured at 37°C and 5% CO2. We built the hypoxia/reoxygenation (H/R) model as described previously (27, 28). Under an oxygen-free atmosphere (5% CO2, 95% N2, at 37°C), the cells were cultured in low glucose DMEM (1 mg/mL glucose), incubated for 8 h, and then moved into a normal culture medium (4.5 mg/mL glucose) for 48 h under a normal atmosphere (5% CO2 at 37°C).

lncRNA-HRAT and control lentivirus were purchased from Genechem (Shanghai, China). For lentivirus infection, after plating into 6-well plates with 30-50% confluence 24 h before use, H9c2 cells were then infected with lncRNA-HRAT lentivirus or control lentivirus at MOI = 20 for 12 h, and then placed in fresh culture medium.

Animal

Healthy C57BL/6 male mice (weight 25-30 g, 10-12 weeks old) were purchased from the Hunan SJA Laboratory Animal Company (Changsha, China). LncRNA-HRAT floxed mice and αMyHC-Cre transgenic mice were purchased from Cyagen Biosciences (Guangzhou, China). LncRNA-HRAT floxed mice were crossed-breeding with αMyHC-Cre transgenic mice to generate cardiomyocyte-specific lncRNA-HRAT knockout (HRAT CKO) mice. Mice were kept under a 12 h light/dark cycle at 25°C, water and food were freely accessible. The Animal Research Committee of the Center of Central South University...
Zheng et al. 10.3389/fcvm.2022.951463

(grant 2019sydw0160) approved the animal experimental procedures, which were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011).

**Myocardial ischemia/reperfusion injury model**

Pentobarbital sodium (1%, 50 mg/kg intraperitoneally [i.p.]; Sigma-Aldrich, United States) was used to anesthetize age- and weight-matched male mice. Once anesthetized, the mice were intubated, and an animal ventilator (Taimeng, Chengdu, China) was used for ventilation. The left chest was opened at the fourth intercostal space, and the heart smoothly and gently "popped out" through the fourth intercostal space. 0.5 cm below the left auricle, a 6-0 silk suture was utilized to tie a slipknot around the left anterior descending coronary artery. The heart was quickly returned to the chest, the air was evacuated manually, and the skin was closed. After 45 min of ischemia, the slipknot was loosened to allow reperfusion. The sham group underwent the same procedure; however, the left coronary artery was not ligated.

**Measurement of serum creatine kinase**

A creatine kinase (CK) detection kit (Nanjing Jiancheng, Jiangsu, China) was used to measure CK activity in the serum of mice, according to the manufacturer's instructions. For each well, the absorbance was measured using a microplate reader (Tecan, Switzerland) at 660 nm.

**2, 3, 5-triphenyl tetrazolium chloride staining**

Twenty-four hours after reperfusion, the heart was resected and processed into five slices quickly. After washing with 0.9% saline, the slices were stained in the dark for 15 min with 1.0% TTC solution (Sigma-Aldrich, United States) at 37°C, and photographed. ImageJ software was used to examine the total area of the transverse section and the area of infarction, and the values obtained were averaged. The ratio of infarct size to the total area of the transverse section was defined as the infarct size (%).

**Echocardiography**

Mice were anesthetized at day 7 after sham operation or I/R by isoflurane and echocardiography was performed utilizing a Vevo2100 high-resolution imaging system accompanied by a 30-MHz high-frequency transducer (FUJIFILM Visual Sonics, Canada) as described previously (29). The left ventricular (LV) internal diameter was measured for at least three beats in two-dimensional M-mode and then averaged. Left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVEDS) were examined, and matched software was utilized to compute the left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF).

**RNA sequencing analysis**

RNA sequencing experiments were performed by RiboBio Company (Guangzhou, China). In brief, samples (two H/R treatment and two normal oxygen groups) were purified and subjected to cDNA synthesis, and subsequently underwent adaptor ligation and amplification using NEBNext® Ultra™ RNA Library Prep Kit for Illumina (NEB, United States), as per manufacturer's instructions. After assessment with the Agilent 2200 TapeStation and Qubit® 2.0 (Life Technologies, United States), the purified library products were diluted to 10 pM to generate clusters on the pair-end flow cell in situ, and then sequenced (2 × 150 bp) using Illumina HiSeq3000.

After removing the low-quality reads with adapters and poly-N from the raw data, HISAT2 was used to map the clean reads to the reference genome of Rat (rn6). Subsequently, the mapped short reads were converted to read counts via HTSeq. Using the read counts as input, DEseq was applied to evaluate differential expression. Multiple testing correction with the Benjamini-Hochberg approach was adopted. For differentially expressed genes, the thresholds for identification were adjusted to p-value less than 0.05 and fold change more than 2.

**MiRNA reagents and their application**

The miRNA mimics were purchased from GenePharma (Shanghai, China). RiboFect™ CP Reagent (RiboBio, Guangzhou, China) was used for in vitro transfection of miRNA mimics. H9c2 cells were developed in 6-well plates with 30-50% confluence 24 h before use and then transfected with miRNA mimic, as per manufacturer’s instructions. After transfection for 48 h, further assays were performed.

**Luciferase reporter assay**

The mutant and wild-type (WT) regions of IncRNA-HRAT and RNF41, accompanied by assumed sites binding with miR-370-3p, were synthesized, followed by construction into the GP-miRGLO-control reporter vector (GenePharma, Shanghai, China). HEK-293T cells were plated into 12-well plates 24 h before transfection, and the corresponding plasmids, miR-370-3p or NC mimics, were used for co-transfection. After
48 h, the dual luciferase reporter assay kit (Promega, Madison, United States) was used, as per manufacturer's instructions, to test the activities of firefly and Renilla luciferase. The activity of firefly luciferase was standardized to that of Renilla luciferase, as described previously (30).

RNA immunoprecipitation assay

RIP assay was performed using the Magna RNA-Binding Protein immunoprecipitation kit (Millipore, MA, United States), as per manufacturer's instructions. Briefly, after transfection for 48 h with miR-370-3p or NC mimic, H9c2 cells were harvested, resuspended in RIP lysis buffer, and incubated for 5 min on ice. The cell extract and magnetic beads conjugated with 5 µg of Ago2 antibody (Cell Signaling Technology, 2897S) or IgG antibody (Millipore, PP64B) were incubated together. Rabbit IgG was used as the negative control. Magnetic beads were resuspended in the washing buffer. To separate the RNA-protein complexes from the beads, proteinase K was incubated with magnetic beads for 30 min at 55°C. After RNA extraction, lncRNA-HRAT expression in immunoprecipitated RNA was determined using qRT-PCR.

RNA pulldown assay

The biotinylated HRAT probe was synthesized by the RiboBio Company (Guangzhou, China). After washing with cold PBS, approximately 3 × 10^7 H9c2 cells were lysed using RIP lysis buffer. Subsequently, 1 µg of probe was added to 50 µL prewashed streptavidin beads, blended lightly, and incubated for 2 h at 4°C. The lysates were incubated overnight with probe-coated beads at 4°C. After binding to the beads, the RNA complexes were eluted and subjected to qRT-PCR to measure the miR-370-3p expression.

Assessment the protein-coding potential of lncRNA-HRAT

To analyze the possibility of lncRNA-HRAT coding, we employed the Coding Potential Calculator Online software as described previously (11, 31). The lncRNA-HRAT sequence was used to automatically calculate its coding potential capacity, and the mRNA of TP53 and β-actin was regarded as the positive control of the coding gene (data not shown).

Nuclear and cytoplasmic RNA isolation

To explore the cell location of lncRNA-HRAT, cytoplasmic and nuclear fractions were isolated and collected using the PARIS Kit (Life Technologies, CA, United States), according to the manufacturer's instructions. The extracted RNA was analyzed by qRT-PCR to detect the expression of the cytoplasmic control transcript GAPDH and β-actin, nuclear control transcript U6, and lncRNA-HRAT.

RNA fluorescent in situ hybridization analysis

RNA FISH was performed using a FISH Kit (RiboBio, Guangzhou, China) with probes targeting lncRNA-HRAT and probes targeting r-18S, following the manufacturer's protocol.

Flow cytometry analysis

The Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, CA, United States) was used to perform flow cytometry to measure the apoptotic rate. Briefly, after harvest, the floating and attached cells were washed with cold PBS, resuspended in Annexin V binding buffer, stained with Annexin V-FITC and PI, and then analyzed by flow cytometry. The flow cytometer (BD Biosciences, CA, United States) was used to measure 1 × 10^6 cells for each experiment, and Flow Jo v10.2 (BD Biosciences, CA, United States) was used for analysis. The impact of lncRNA-HRAT on apoptosis triggered by H/R was tested using Annexin V-APC and 7-AAD (BD Biosciences, CA, United States). The methods used were similar to those used for the Annexin V-FITC Apoptosis Detection Kit.

RNA extraction and qRT-PCR analysis

Total RNA was extracted from the cultured cells and mouse heart tissues using TRizol reagent (Invitrogen, Carlsbad, CA, United States), as per manufacturer's instructions. Briefly, a Reverse Transcription Kit (Takara, Dalian, China) was used to reverse transcription of 1,000 ng total RNA to cDNA. For miRNA, based on the manufacturer's instructions and our published papers, a miRNA cDNA Synthesis Kit (Cwbio, Beijing, China) was used for reverse transcription of 2,000 ng of total RNA to cDNA (28, 32). Following the manufacturer's instructions, the cDNA obtained was subjected to real-time PCR using SYBR Green (Bio-Rad, Hercules, California, United States). For miRNA, following the instructions of the manufacturer and our previous studies, the resulting cDNA was subjected to real-time PCR using the miRNA qPCR Assay Kit (Cwbio, Beijing, China) (28, 32). GAPDH and U6 were used as normalized controls. The fold-change was computed via the 2^−ΔΔCt analytic approach. The remaining primers used are listed in Supplementary Table 1.
Western blot assay and antibodies

RIPA lysis buffer (Beyotime, Shanghai, China) was used to obtain total proteins. Loaded on a 12% SDS-PAGE gel, a 30 μg protein sample was then transferred onto 0.22 μm polyvinylidene fluoride membrane (Millipore, MA, United States). After blocking with 5% milk at RT, the membrane was then incubated with antibodies against β-actin (1:5000, Proteintech, 20536-1-AP), GAPDH (1:1000, Proteintech, 10494-1-AP), Caspase-3 (1:1000, CST, 9662S), cleaved Caspase-3 (1:1000, CST, 9664S), RNF41 (1:1000, Proteintech, 17233-1-AP) overnight at 4°C. β-actin and GAPDH antibody was served as control. An enhanced chemiluminescent detection kit (NCM Biotech, Suzhou, China) was used to visualize the membranes, and image software (Version 5.1, Bio-Rad, CA, United States) was used to perform the densitometric analysis.

Statistical analysis

The data are presented as the mean ± SD. Student’s t-test (two-tailed) was applied to analyze the data between groups, and one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was adopted for analysis among multiple groups. P value < 0.05 was significant statistically. SPSS analyses were performed using analysis 23.0.

Results

H/R induces lncRNA-HRAT expression

To determine which lncRNAs may contribute to cardiomyocyte injury caused by H/R, H9c2 cardiomyocytes were treated with or without H/R, and RNA sequencing analysis was performed. 51 differentially expressed lncRNAs were detected at a threshold of fold change > 3 (Figure 1A). Among these lncRNAs, 19 were upregulated and 32 were downregulated. We selected 7 lncRNAs (Figure 1B) accompanied by the following properties: (a) expression fold change > 4.5 after H/R treatment. (b) No overlap or splicing with any coding gene existing in the Ensembl genome browser annotations, University of California Santa Cruz Genome Browse, and the National Center for Biotechnology Information’s RefSeq database. The expression of the selected lncRNAs was verified using qRT-PCR (Figure 1C). Similar results for the two lncRNAs were obtained from the RNA sequencing analysis. Among the two most differentially expressed lncRNAs, a novel lncRNA TCONS_00029632 was significantly upregulated during H/R. We named this lncRNA-Hypoxia/reoxygenation-associated transcript (lncRNA-HRAT). Therefore, lncRNA-HRAT was selected for further study.

Overexpression of lncRNA-HRAT promotes H/R-induced apoptosis in cardiomyocyte

To study the role of lncRNA-HRAT in H/R-induced cardiomyocyte injury, we used lncRNA-HRAT-overexpressing lentivirus to increase the expression of lncRNA-HRAT. We found that when infected with lncRNA-HRAT-overexpressing lentivirus, the expression of lncRNA-HRAT was significantly raised (Figure 2A). Furthermore, in comparison to the control H/R group, overexpression of lncRNA-HRAT dramatically enhanced cleaved-caspase-3 levels (Figure 2B). In contrast, knockdown of the lncRNA-HRAT significantly inhibited the expression of cleaved-caspase-3 (Figures 2C,D). We then performed flow cytometric analysis to detect apoptosis. Compared to the control H/R group, the percentage of apoptotic cells was significantly increased in the lncRNA-HRAT H/R group (Figure 2E). In summary, these data suggest that lncRNA-HRAT promotes H/R-induced apoptosis of cardiomyocytes.

Characterization of lncRNA-HRAT

Our coding potential calculator online analysis revealed that lncRNA-HRAT had no coding potential (Figure 3A). lncRNA-HRAT resides on chromosome 13q13 and is localized near the coding gene adenosine A1 receptor (Adora1) (Figure 3B). It has been reported that lncRNAs have cis-regulatory effects on neighboring genes (33). Thereafter, we evaluated whether lncRNA-HRAT would have an impact on the expression of nearby genes in cis. Notably, Adora1 expression was significantly downregulated during H/R (Figure 3C). Overexpression of lncRNA-HRAT dramatically decreased Adora1 expression (Figure 3D), revealing that lncRNA-HRAT affected the expression of nearby genes in cis. Subsequently, we determined the location of the lncRNA-HRAT in H9c2 cardiomyocytes. FISH and qRT-PCR analyses indicated that lncRNA-HRAT was present in both the nucleus and the cytoplasm (Figures 3E,F). Therefore, lncRNA-HRAT interacts with cytoplasmic molecules or proteins.

Cardiomyocyte-specific deficiency of lncRNA-HRAT alleviates myocardial I/R injury in mice

To detect the possible participation of lncRNA-HRAT in myocardial I/R injury, a myocardial I/R model in mice was built, and qRT-PCR was applied to test the expression of lncRNA-HRAT. The results revealed that lncRNA-HRAT was markedly increased in mouse hearts in the model (Figure 4A), indicating that lncRNA-HRAT may contribute to myocardial I/R injury. To investigate the role...
FIGURE 1

H/R alters the expression of lncRNAs. (A) Heat map of RNA sequencing results of dysregulated lncRNAs (fold change > 3) in Ctrl and H/R cells. (B) Seven novel lncRNAs with the most obvious alterations in H/R-treated H9c2 cells. (C) The expression of seven selected lncRNAs in Ctrl and H/R cells were analyzed by qRT-PCR (n = 5). The Data are presented as means ± SD. *P < 0.05, **P < 0.01, ns = not significant.

of lncRNA-HRAT in myocardial I/R injury, we crossed breeding lncRNA-HRAT floxed mice with α-MyHC-Cre transgenic mice to obtain cardiomyocyte-specific lncRNA-HRAT knockout (HRAT\textsuperscript{flox/flox}; Cre\textsuperscript{α-MyHC} (HRAT CKO)) mice. The strategy for generating HRAT CKO mice is shown in Supplementary Figure 3. The qRT-PCR results confirmed that lncRNA-HRAT was significantly reduced in the hearts of HRAT CKO mice but not in other tissues tested (Figure 4B).

To assess the role of lncRNA-HRAT in myocardial I/R injury, HRAT CKO and HRAT\textsuperscript{flox/flox} mice underwent ischemia for 45 min and reperfusion for 24 h. In addition, the myocardial infarct area was evidently decreased in HRAT CKO mice compared to HRAT\textsuperscript{flox/flox} mice (Figure 4C). The release of creatine kinase (CK) in the serum, an index of myocardial injury, was also significantly decreased in HRAT CKO mice (Figure 4D). To evaluate whether lncRNA-HRAT altered cardiac function following ischemia/reperfusion, we subjected mice to I/R and assessed cardiac function using echocardiography. Our results showed that lncRNA-HRAT knockout significantly improved LVEF (%) and LVFS (%) in I/R injured mice (Figure 4E). These results revealed that lncRNA-HRAT deficiency protects against myocardial I/R injury.

LncRNA-HRAT directly regulates miR-370-3p

New evidence suggests that cytoplasmic lncRNAs modulate the function of miRNAs by serving as ceRNAs. Thereafter, we analyzed the potential interacting miRNAs of lncRNA-HRAT using RNAhybrid, Miranda, and PITA. The results showed that 16 miRNAs formed complementary base pairs with lncRNA-HRAT (Supplementary Table2). The qRT-PCR data implied that miR-3473 and miR-370-3p were markedly decreased in cardiomyocytes after H/R (Supplementary Figure 4A). Moreover, overexpression of lncRNA-HRAT markedly decreased miR-370-3p expression but not miR-3473 (Supplementary Figure 4B). Therefore, miR-370-3p was selected for subsequent experiments.

The predicted binding sites of lncRNA-HRAT and miR-370-3p are shown in Figure 5A. A dual-luciferase reporter assay was used to examine whether lncRNA-HRAT directly binds to miR-370-3p. The results indicated that miR-370-3p mimics markedly reduced luciferase activity in the WT lncRNA-HRAT reporter vector but not in the mutant lncRNA-HRAT (Figure 5B), suggesting that the binding of lncRNA-HRAT to miR-370-3p is sequence-specific. It has been reported that
miRNAs bind to their targets and trigger the degradation of RNA and translational repression in an Argonaute2 (Ago2)-dependent manner (34, 35). To investigate whether lncRNA-HRAT could be regulated by miR-370-3p in this manner, an RIP assay was applied to Ago2. The results demonstrated that lncRNA-HRAT binds to miR-370-3p via Ago2 (Figure 5C).

Moreover, RNA pulldown assay revealed that miR-370-3p was significantly enriched in the lncRNA-HRAT group (Figure 5D). Subsequently, the relationship between miR-370-3p and the lncRNA-HRAT was investigated. Importantly, lncRNA-HRAT overexpression significantly inhibited miR-370-3p expression (Figure 5E), whereas the expression levels of miR-370-3p were...
FIGURE 3
Characterization of lncRNA-HRAT. (A) Assessment the protein-coding potential of lncRNA-HRAT by Coding Potential Calculator Online. (B) Schematic annotation of the lncRNA-HRAT genomic locus. (C) The analysis of Adora1 expression in Ctrl and H/R cells was conducted through qRT-PCR (n = 3). (D) The analysis of Adora1 expression in H9c2 cells infected with lncRNA-HRAT or control lentivirus was conducted through qRT-PCR (n = 3). (E) The localization of lncRNA-HRAT in H9c2 cells was tested via RNA FISH (n = 3). Nuclei was stained with 4,6-diamidino-2-phenylindole (DAPI; blue), 18S and lncRNA-HRAT appeared red. Scale bar, 10 µm. (F) The analysis of lncRNA-HRAT expression in the nucleus and cytoplasm of H9c2 cells was employed through qRT-PCR (n = 3). The cytoplasmic control was GAPDH and β-actin, while the nuclear control was U6. All the data are described as the mean ± SD. *P < 0.05.

significantly increased in HRAT CKO mice subjected to I/R (Figure 5F). However, when transfected with the miR-370-3p mimic, no obvious differences were observed in the lncRNA-HRAT levels (Figure 5G). Thus, these results revealed that lncRNA-HRAT directly binds to and negatively regulates miR-370-3p.

MiR-370-3p suppresses H/R-induced cardiomyocyte apoptosis

The effect of miR-370-3p on H/R-induced cardiomyocyte injury was assessed. We revealed that miR-370-3p was markedly reduced in I/R injured mouse hearts (Figure 6A) and H/R-treated cardiomyocytes (Figure 6B). After transfection with miR-370-3p mimics, miR-370-3p exhibited a dramatic increase in expression, indicating successful transfection (Figure 6C). MiR-370-3p overexpression significantly decreased cleaved-caspase-3 expression caused by H/R, compared to that in the negative controls (Figure 6D). Moreover, a reduction in the percentage of apoptotic cells was observed when miR-370-3p was overexpressed (Figure 6E). In summary, our results demonstrated that miR-370-3p overexpression attenuates H/R-induced apoptosis in cardiomyocytes.

RNF41 is a downstream target of miR-370-3p

To further evaluate the mechanism underlying the contribution of the lncRNA-HRAT-miR-370-3p pathway to the pro-apoptotic effect on cardiomyocytes, we utilized TargetScan, miRWalk, and miRDB software to predict miR-370-3p target genes. We focused on RNF41 (also known as Nrdp1), which plays a pro-apoptotic role in myocardial I/R injury (36). Figure 7A displays the predicted binding sites between miR-370-3p and RNF41. The dual-luciferase reporter assay results revealed that miR-370-3p mimics significantly decreased the luciferase activity of the WT RNF41 reporter vector, but not the mutant RNF41 (Figure 7B). QRT-PCR and western blotting results indicated that miR-370-3p overexpression markedly diminished RNF41 expression (Figures 7C,D). Thus, these findings suggest that miR-370-3p directly binds to RNF41 and negatively regulates RNF41.

We further studied the impact of lncRNA-HRAT on the miR-370-3p downstream target RNF41. As shown in Figure 7E, lncRNA-HRAT overexpression increased RNF41 expression. Notably, miR-370-3p overexpression by transfection with the miR-370-3p mimic significantly diminished RNF41.
expression induced by the overexpression of lncRNA-HRAT (Figure 7E). Moreover, H/R also increased the expression of RNF41 (Figure 7F). In contrast, the expression of RNF41 was significantly decreased in HRAT CKO mice subjected to I/R (Figure 7G). Therefore, these data revealed that lncRNA-HRAT serves as a ceRNA of miR-370-3p to modulate RNF41 expression.

Discussion

Myocardial ischemia causes various conditions, such as cardiac dysfunction, arrhythmias, myocardial infarction, and even sudden death. Reperfusion causes excess cell death and an increase in infarct size, known as myocardial I/R injury (37–39). During the past few decades, many bioprocesses
and protein-coding genes have been shown to participate in myocardial I/R injury. However, the mechanisms underlying myocardial I/R injury remain unclear. LncRNAs play a strong role in the development of the heart and pathophysiological processes of cardiovascular diseases (40, 41). Previous research has indicated that many lncRNAs are abnormally expressed in the heart during the early stage of reperfusion after ischemia (16). Recently, several studies have shown that lncRNAs regulate apoptosis, oxidative stress, and inflammatory responses through miRNAs or target genes, thereby modulating myocardial I/R injury (42–44). Although many lncRNAs have proved to participate in myocardial I/R injury, the existence of other lncRNAs that regulate myocardial I/R injury requires further investigation.

In this study, we identified numerous aberrantly expressed lncRNAs in H9c2 cardiomyocytes during H/R. Seven lncRNAs

![FIGURE 5](image-url)
FIGURE 6
MiR-370-3p overexpression suppresses the apoptosis triggered by H/R in cardiomyocytes. (A) The analysis of miR-370-3p expression in I/R (45/3 hr) and sham mice hearts was carried out through qRT-PCR (n = 5). (B) The analysis of miR-370-3p expression in Ctrl and H/R cells was employed via qRT-PCR (n = 3). (C) The analysis of miR-370-3p expression in H9c2 cells with or without miR-370-3p mimics was conducted through qRT-PCR (n = 3). (D) Protein levels of caspase-3 and cleaved-caspase-3 in different groups of cells were tested via Western blot (n = 3). (E) The apoptotic cell rate in H9c2 cells was examined via flow cytometry (n = 3). All the data are described as the mean ± SD. *P < 0.05, **P < 0.01.
FIGURE 7

RNF41 is a downstream target of miR-370-3p. (A) Predicted binding site between RNF41 and miR-370-3p. (B) The relative luciferase activity of the RNF41 wild-type/mutant reporter in HEK-293T cells with or without miR-370-3p mimics was analyzed by dual luciferase reporter assay (n = 3). mRNA (C) and Protein (D) levels of RNF41 in H9c2 cells with or without miR-370-3p mimics (n = 3). (E) Protein levels of RNF41 in different groups of cells were tested via Western blot (n = 3). (F) Protein levels of RNF41 in Ctrl and H/R cells were examined by Western blot (n = 3). (G) Protein levels of RNF41 in the hearts from HRAT<sup>F</sup>F and HRAT CKO mice subjected to I/R (45'/3 hr) was detected by Western blot (n = 5). All the data are described as the mean ± SD. *P < 0.05, **P < 0.01, ns = not significant.

that may function in H/R injury were identified, and their corresponding expression was validated using qRT-PCR. The variation tendency of the two lncRNAs was consistent with the RNA sequencing results. In addition, we focused on a novel lncRNA, HRAT (lncRNA TCONS_00029632), which was significantly increased in H9c2 cardiomyocytes treated with H/R. By applying gain-of-function methods, we determined that overexpression of lncRNA-HRAT exacerbated cardiomyocyte injury by promoting apoptosis during H/R. In addition, an in vivo study indicated that lncRNA-HRAT expression was markedly upregulated following I/R treatment. Cardiomyocyte-specific deficiency of lncRNA-HRAT significantly decreased the release of CK in the serum, reduced myocardial infarct area, and improved cardiac dysfunction. Our
results suggest that the lncRNA-HRAT has a detrimental effect on myocardial I/R injury.

Some lncRNAs influence the expression of neighboring genes by acting in cis (45). Diffusing from their transcription sites, other lncRNAs influence genes located on different chromosomes by acting in trans (11, 46, 47). In this study, we observed that lncRNA-HRAT overexpression decreased the expression of the neighboring gene Adora1, indicating that lncRNA-HRAT affects the expression of nearby genes in cis. A previous study indicated that the overexpression of Adora1 decreased I/R-induced apoptosis in the heart (48). Furthermore, in isolated rat hearts, activation of Adora1 by an agonist reduces I/R injury (49). However, the mechanisms by which IncRNA-HRAT modulates Adora1 expression in myocardial I/R injury remain unclear. This is interesting and will be investigated in future studies.

As endogenous sponge RNAs, IncRNAs may interact with miRNAs and affect miRNA target gene expression (50, 51). The interactions discovered between IncRNAs and miRNAs have inspired us (34), and we sought to identify miRNAs accompanied by complementary base pairing with IncRNA-HRAT. Both luciferase and Ago2 RIP assays demonstrated that miR-370-3p binds to IncRNA-HRAT directly. RNA pulldown assay further verified the directional binding of IncRNA-HRAT to miR-370-3p. In addition, IncRNA-HRAT overexpression declined the expression of miR-370-3p in H9c2 cardiomyocytes. However, miR-370-3p overexpression showed no obvious differences in the IncRNA-HRAT levels. Our studies revealed that IncRNA-HRAT binds to miR-370-3p directly and negatively regulates its expression of miR-370-3p.

MiR-370-3p is involved in suppressing the proliferation and invasion in various types of cancer cells (21–23). Hou et al. reported that miR-370-3p also suppresses the proliferation of human vascular smooth muscle cells in cerebral aneurysms by targeting KDR and blocking the AKT/FOXO1 signaling pathway (52). Recent studies have suggested that miR-370-3p inhibits hypoxia-induced cardiomyocyte injury (24–26). In this study, we revealed that miR-370-3p overexpression inhibited H/R-induced apoptosis in cardiomyocytes.

RNF41 (also known as Nrdp1), a RING finger E3 ubiquitin ligase, is mainly expressed in skeletal muscle, brain, and heart (36). RNF41 regulates oxidative stress, inflammation, apoptosis, and cell proliferation (53–55). A previous study demonstrated that overexpression of RNF41 promotes cardiomyocyte apoptosis and inflammation induced by myocardial I/R injury (36). However, the relationship between miR-370-3p and RNF41 in I/R injury remains unknown. In this study, we found that RNF41 is a downstream target of miR-370-3p in I/R injury. MiR-370-3p negatively regulates RNF41 expression.

LncRNA-H19 binds to miR-370-3p directly and serves as a ceRNA to facilitate the epithelial-mesenchymal transition (EMT) in ovarian cancer cells induced by TGF-β (56). Recent studies indicate that lncRNA-FGF14-AS2 serves as a tumor inhibitor by sponging miR-370-3p, which has an inhibitory effect on FGF14, thereby restraining the migration and invasion of breast cancer cells (57). Similarly, our results revealed that lncRNA-HRAT serves as a ceRNA of miR-370-3p and increases RNF41 expression, thereby aggravating H/R-induced apoptosis in cardiomyocytes.

In summary, we identified and characterized a novel lncRNA HRAT, which regulates cardiomyocyte apoptosis and myocardial injury during I/R. Our research revealed that the lncRNA-HRAT/miR-370-3p/RNF41 pathway plays a strong role in regulating cardiomyocyte apoptosis and myocardial injury. Our findings imply that lncRNA-HRAT may be a possible target for the treatment of myocardial I/R injury. This study provides novel insights into the mechanisms underlying myocardial I/R injury.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://figshare.com/s/dc534de95cf6b3c379b.

Ethics statement

The animal study was reviewed and approved by Animal Research Committee of Center of Central South University (grants 2019sydw0160).

Author contributions

XZ, DS, and DY conceived and designed this study and wrote the manuscript. XZ, TZ, FY , JD, YT, and YL conducted the experiments. XZ and ML performed data analysis. FY interpreted the results of the experiments. All authors reviewed and approved the final version of the manuscript.

Funding

This study was funded by the National Science Foundation of China (Grant Nos. 82170242, 81570454, and 81773012).

Acknowledgments

We thank all our colleagues on the research team for their technical assistance.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.951463/full#supplementary-material

References

1. Wang X, Zhang X, Ren XP, Chen J, Liu H, Yang J, et al. Microrna-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. (2010) 122:1308–18. doi: 10.1161/CIRCULATIONAHA.110.964684
2. Matsuda T, Zhai P, Sciarretta S, Zhang Y, Jie P, Ikeda S, et al. NF2 activates hippo signaling and promotes ischemia/reperfusion injury in the heart. Circ Res. (2016) 119:586–606. doi: 10.1161/CIRCRESAHA.116.308386
3. Ren XP, Wu J, Wang X, Sartor MA, Jones K, Qian J, et al. Microrna-320 is involved in the regulation of cardiaco ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation. (2009) 119:2357–66. doi: 10.1161/CIRCULATIONAHA.108.814155
4. Liu Y, Zhou D, Li G, Ming X, Tu Y, Tian J, et al. Long non coding rna-ucal contributes to cardiomyocyte apoptosis by suppression of p27 expression. Cell Physiol Biochem. (2015) 35:1986–98. doi: 10.1159/000374806
5. Huang Z, Wu S, Kong F, Cai X, Ye B, Pan P, et al. Microrna-21 protects against cardiac hypoxia/reoxygenation injury by inhibiting excessive autophagy in H9c2 Cells via the Akt/Mtor pathway. J Cell Mol Med. (2017) 21:467–74. doi: 10.1111/jcmm.12990
6. Muntean DM, Staurna A, Danila MD, Borza C, Duscu OM, Mornos C. The role of mitochondrial reactive oxygen species in cardiovascular injury and protective strategies. Oxid Med Cell Longev. (2016) 2016;8254942. doi: 10.1155/2016/8254942
7. Li Z, Zhang Y, Ding N, Zhao Y, Ye Z, Shen L, et al. Inhibition of Lcnrna Xst improves myocardial I/R injury by targeting Mir-133a through inhibition of autophagy and regulation of Socs2. Mol Ther Nucleic Acids. (2019) 18:764–73. doi: 10.1016/j.omtn.2019.10.004
8. Shigematsu T, wolf RE, Granger DNT-. Lymphocytes modulate the microvascular and inflammatory responses to intestinal ischaemia-reperfusion. Microcirculation. (2002) 9:99–109. doi: 10.1111/j.8080.2002.00216.x
9. Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA. (2016) 113:2672–80. doi: 10.1073/pnas.1820211216
10. Alvarez-Dominguez JR, Lodish HF. Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. (2017) 130:1965–75. doi: 10.1182/blood.2017-06-786695
11. Ma MZ, Zhang Y, Weng MZ, Wang SH, Hu Y, Hou ZY, et al. Long noncoding RNA Gcaspuc, a target of mir-17-5p, negatively regulates pyruvate carboxylase-dependent cell proliferation in gallbladder cancer. Cancer Res. (2016) 76:3561–71. doi: 10.1158/0008-5472.CAN-15-3047
12. Wu H, Zhu H, Zhang Y, Zhang J, Ding X, Zhan L, et al. LncRNA Acart protects cardiomyocytes from apoptosis by activating PPAR-Gamma/Rel-2 pathway. J Cell Mol Med. (2020) 24:373–8. doi: 10.1111/jcmm.14781
13. Saha S, Kisan M, Kuscu C, Charath A, Wotton D, Mayo MW, et al. Long noncoding RNA drac induces prostate cancer progression by interacting with IKK to inhibit NF-Kappab activation. Cancer Res. (2020) 80:950–63. doi: 10.1158/0008-5472.CAN-19-2346
14. Gandha S, Ruebel E, Stall M. Evolutionary patterns of non-coding RNA in cardiovascular biology. Noncoding RNA. (2019) 5:15. doi: 10.3390/ncrna5010015
15. Uchida S, Dimmel S. Long noncoding RNAs in cardiovascular diseases. Circ Res. (2015) 116:737–50. doi: 10.1161/CIRCRESAHA.116.302521
16. Liu Y, Li G, Lu H, Li W, Li X, Liu H, et al. Expression profiling and ontology analysis of long noncoding RNAs in post ischemic heart and their implied roles in ischemia/reperfusion injury. Gene. (2014) re415–21. doi: 10.1016/j.gene.2014.04.016
17. Li X, Luo S, Zhang J, Yuan Y, Jiang W, Zhi H, et al. Lncrna H19 alleviated myocardial I/R via suppressing Mir-877-3p/Bcl-2-mediated mitochondrial apoptosis. Mol Ther Nucleic Acids. (2019) 17:297–309. doi: 10.1016/j.omtn.2019.05.031
18. Su Q, Liu Y, Lv XW, Ye ZL, Sun YH, Kong BH, et al. Inhibition of Lncrna Tugi upregulates Mir-142-3p to ameliorate myocardial injury during ischemia and reperfusion via targeting Hmgbl-1 and Rac1-induced apoptosis. J Mol Cell Cardiol. (2019) 133:12–23. doi: 10.1016/j.yjmcc.2019.05.021
19. Kong F, Jin J, Lv X, Han Y, Liang X, Gao Y, et al. Long noncoding RNA RMBP upregulation aggravates myocardial ischemia-reperfusion injury by sponging Mir-206 to target Atg3 expression. Biomed Pharmacother. (2019) 109:716–25. doi: 10.1016/j.biopha.2018.10.079
20. Lin L, Wang D, Qu S, Zhao H, Lin Y. Mir-370-3p alleviates ulcerative colitis-related colorectal cancer in mice through inhibiting the inflammatory response and epithelial-mesenchymal transition. Drug Des Devel Ther. (2020) 14:1127–41. doi: 10.2147/DDDT.S238124
30. Lin Z, Zhou Z, Guo H, He Y, Pang X, Zhang X, et al. Long noncoding RNA gastric cancer-related IncRNA mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4. Cell Death Dis. (2018) 9:6077. doi: 10.1038/s41419-018-0643-5

31. Kong L, Zhang Y, Ye QZ, Liu SQ, Zhao SQ, Wei L, et al. CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res. (2007) 35:W345-9. doi: 10.1093/nar/gkm391

32. Qi S, Feng Y, Leefage G, Zhang Y, Stuart C, He L, et al. Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating P65 and Traff. J Immunol. (2015) 194:1021-30. doi: 10.4049/jimmunol.1400106

33. Yang T, Chen WC, Shi PC, Liu MR, Jiang T, Song H, et al. Long noncoding RNA Mapkapk5-As1 promotes colorectal cancer progression by CIS-regulating the nearby gene MKS and acting as a Let-7f-3p sponge. J Exp Clin Cancer Res. (2020) 39:129. doi: 10.1186/s13046-020-00138-8

34. Liu F, Yuan JH, Huang JF, Yang F, Wang TT, MA JZ, et al. Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding Mcm2 and Mir-374a. Oncoene. (2016) 35:5422-34. doi: 10.3390/oncoene.2016.80

35. Guo Z, Wang X, Yang Y, Chen W, Zhang K, Teng B, et al. Hypospic tumor-derived exosomal long noncoding RNA LCA1 promotes angiogenesis via Mr-96-5p/Amotl2 in pancreatic cancer. Mol Ther Nucleic Acids. (2020) 22:179-95. doi: 10.1016/j.omtn.2020.08.021

36. Zhang Y, Zeng Y, Wang M, Tian C, Ma X, Chen H, et al. Cardiac-specific overexpression of E3 Ligase Nrdp1 increases ischemia and reperfusion-induced cardiac injury. Basic Res Cardiol. (2011) 106:371-83. doi: 10.1007/s00395-011-0157-0

37. Zhang SB, Liu TJ, Pu GH, Li BY, Gao XZ, Han XL. Suppression of long non-coding RNA Linc00652 restores sevoflurane-induced cardioprotection against myocardial ischemia-reperfusion injury by targeting Glp-1r through the Camp/Pka pathway in mice. Cell Physiol Biochem. (2018) 49:1476-91. doi: 10.1007/s00973-018-5944-0

38. Huang Z, Ye B, Dai Z, Wu X, Lu Z, Shan P, et al. Curcumin inhibits apoptosis and autophagy in hypoxia/reoxygenation-induced myocytes. Mol Med Rep. (2015) 11:4678-84. doi: 10.3892/mmr.2015.3322

39. Luo H, Wang J, Liu D, Zang S, Ma N, Zhao L, et al. The IncRNA H19/Mir-675 axis regulates myocardial ischemia and reperfusion injury by targeting Pparalpha. Mol Immunol. (2019) 105:46-54. doi: 10.1016/j.molimm.2018.11.011

40. Archer K, Broskova Z, Bayouni AS, Teoh JP, Davila A, Tang Y, et al. Long non-coding RNAs as master regulators in cardiovascular diseases. Int J Mol Sci. (2015) 16:23651-67. doi: 10.3390/ijms161023651

41. Greco S, Salgado Somoza A, Devaux Y, Martelli F. Long noncoding RNAs and protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res. (2007) 35:W345-9. doi: 10.1093/nar/gkm391

42. Sun T, Cheng YT, Yan LX, Krittanawong C, Qian W, Zhang HJ. LncRNA malat1 knockdown alleviates myocardial apoptosis in rats with myocardial ischemia-reperfusion injury. Eur Rev Med Pharmacol Sci. (2019) 23:10523-31. doi: 10.26355/eurev_201912_19693

43. Li X, Dai Y, Yan S, Shi Y, Han B, Li J, et al. Down-regulation of LncRNA Kcnq1ot1 protects against myocardial ischemia/reperfusion injury following acute myocardial infarction. Biochim Biophys Acta. (2017) 199:1043-46. doi: 10.1016/j.bbamcr.2017.08.005

44. Liu Q, Liu Z, Zhou L, Cui YL, Xu JM. The long noncoding RNA NKILA protects against myocardial ischemic injury by enhancing myocardial expression via suppressing the NF-Kappab signalling pathway. Exp Cell Res. (2020) 387:111774. doi: 10.1016/j.yexcr.2019.111774

45. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. (2018) 172:393–407. doi: 10.1016/j.cell.2018.01.011

46. Wang P, Xu J, Wang Y, Cao X. An interferon independent lncRNA promotes viral replication by modulating cellular metabolism. Science. (2017) 358:1051–5. doi: 10.1126/science.aao0409

47. Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, et al. The Stat3-binding long noncoding RNA Lnc-DC controls human dendritic cell differentiation. Science. (2014) 344:1303–3. doi: 10.1126/science.1251486

48. Regan SE, Broad M, Byford AM, Lankford AR, Cerny-Bayoumi AS, Teoh JP, Davila A, Tang Y, et al. A novel highly selective adenosine A1 receptor agonist Vcp28 reduces ischemia injury in a cardiac cell line and ischemia-reperfusion injury in isolated rat hearts at concentrations that do not affect heart rate. J Cardiovasc Pharmacol. (2015) 66:282–92. doi: 10.1177/0022351415563800

49. Urmaliya VB, Pouton CW, Devine SM, Haynes JM, Warfe L, Scammell PJ, et al. The novel highly selective adenosine A1 receptor agonist Vcp28 reduces ischemia injury in a cardiac cell line and ischemia-reperfusion injury in isolated rat hearts at concentrations that do not affect heart rate. J Cardiovasc Pharmacol. (2015) 66:282–92. doi: 10.1177/0022351415563800

50. Wang K, Liu F, Zhou L, Long B, Yuan SM, Wang Y, et al. Long noncoding RNA CHR1 regulates cardiac hypertrophy by targeting Mir-489. Circ Res. (2014) 114:1377–88. doi: 10.1161/CIRCRESAHA.114.302476

51. Liang YP, Liu Q, Xu GH, Zhang J, Chen Y, Hua FZ, et al. The LncRNA Rot/MIr-124-3p/Trf axis regulated the ischaemia reperfusion injury-induced inflammatory response in human cardiac myocytes. J Biosener Biomembr. (2019) 51:381–92. doi: 10.1152/ajpph.00192-01812-9

52. Hou WZ, Chen XL, Wu W, Hang CH. MicroRNA-370-3p inhibits human vascular smooth muscle cell proliferation via targeting Kdr/Akt signaling pathway in cerebral aneurysm. Eur Rev Med Pharmacol Sci. (2017) 21:1080–7.

53. Shen J, Song Y, Shen J, Lin Y, Wu X, Yan Y, et al. Nrdp1 is associated with neuronal apoptosis in lipopolysaccharide-induced neuroinflammation. Neurochem Res. (2015) 40:971–9. doi: 10.1007/s11064-015-1552-9

54. Yu E, Zhou J, Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced oxidative stress. Neurosci Lett. (2008) 440:4–8. doi: 10.1016/j.neulet.2008.05.052

55. Wang C, Chen T, Zhang J, Yang M, Li N, Xu X, et al. The E3 ubiquitin ligase Nrdp1 ‘Preferentially’ promotes Trl-mediated production of type 1 interferon. Nat Immunol. (2009) 10:744–52. doi: 10.1038/ni.1742

56. Li J, Huang Y, Deng X, Luo M, Wang X, Hu H, et al. Long noncoding RNA H19 promotes transforming growth factor-beta-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of Mir-370-3p in ovarian cancer cells. Onco Targets Ther. (2018) 11:427–40. doi: 10.2174/OTT.1S149908

57. Jin Y, Zhang M, Duan R, Yang J, Yang W, Jiang T, et al. Long noncoding RNA Fgf14-A2 inhibits breast cancer metastasis by regulating the Mir-370-3p/Fgf14 axis. Cell Death Dis. (2020) 11:603. doi: 10.1038/s41419-020-00334-7